VISICORT consortium mets at the Aarhus University Hospital

VISICORT Aarhus Group Photo 121110

The VISICORT consortium met at the Aarhus University Hospital, Aarhus, Denmark on the 12–13 November for the project’s third plenary meeting. Teams of researchers from each of the twelve partners involved in the project listened to reports of the work being carried out in each of the project’s workpackages. These included reports of the preclinical experimental work being carried out to model corneal rejection in rats and to access the benefits of mesenchymal stem cells (MSCs) in helping to prevent transplant rejection. The consortium was also updated on the progress in recruiting patients to VISICORT’s clinical studies, and the work that has been carried out to support the complex sample and information management needs of this ambitious project.

Commenting on the meeting, VISICORT coordinator Prof. Matthew Griffin (NUIG) said: “It was clear from our meeting in Aarhus that the VISICORT project is now in full swing. We are fortunate to have recruited an exceptional group of front line researchers who are working together across all partner sites to optimise and streamline biological sampling and transport procedures, maximise subject enrolment to our clinical studies, perform and interpret key pre-clinical experiments, and lay the groundwork for advanced immunological profiling and system-level analysis of corneal transplant rejection. The VISICORT consortium has established and integrated two unique assets that serve as a foundation for the next stages of the project: a purpose-designed clinical database of new and established corneal transplant recipients from five leading medical centres developed for us by PathXL, Belfast, Northern Ireland and a centralised bio-repository of samples from these same study subjects at the site of VISICORT partner Biostór Ireland Ltd. In addition, the combined clinical, scientific and technological expertise of the consortium is being harnessed to effectively translate our pre-clinical observations into the first clinical trial protocol for mesenchymal stems cells in corneal transplant recipients at high risk for rejection. We face an exciting time over the next six months with laboratory and clinical studies beginning to yield novel data and insights into the immune responses that determine the success or failure of the most common tissue transplant”.

Prof. Jesper Østergaard Hjortdal (Aarhus University), who hosted the meeting comments: ‘It was a great pleasure to welcome the VISICORT team to Aarhus University Hospital. In addition to progress reports from each workpackage, three workshops were organised in the fields of clinical studies, sample collection, preparation and logging, and bioinformatics. The meeting was held in a very constructive atmosphere, and all indications suggest that the VISICORT project will have a very successful outcome.”

The corneal transplant team at the Department of Ophthalmology at Aarhus University Hospital is the largest in the Nordic countries, and performs around 300 corneal transplantations annually. In addition, the Danish Cornea Bank, which is based at the hospital? distributes more than 400 cornea grafts per year. Corneal transplantations are only performed at two hospitals in Denmark, and the hospital in Aarhus serves more than half of the Danish population (close to 3 million citizens).